25 Boletín Hipertensión VOL 25. 2021 / 20 - 25 Hiperaldosteronismo Primario Referencias 1. Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. 2. Baudrand R, Vaidya A. The Low-Renin Hypertension Phenotype: Genetics and the Role of the Mineralocorticoid Receptor. Int J Mol Sci. 2018;19(2). 3. Hung A, Ahmed S, Gupta A, et al. Performance of the Aldosterone to Renin Ratio as a Screening Test for Primary Aldosteronism. J Clin Endocrinol Metab. 2021;106(8):2423-2435. 4. Brown JM, Siddiqui M, Calhoun DA, et al. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann InternMed. 2020;173(1):10-20. 5. Baudrand R, Guarda FJ, Fardella C, et al. Continuumof Renin-Independent Aldosteronism in Normotension. Hypertension. 2017;69(5):950-956. 6. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351(1):33-41. 7. Rikimaru T, Fujita Y, Okuda T, et al. Responses of sodiumbalance, blood pressure, and other variables to sodium loading in Papua New Guinea highlanders. Am J Clin Nutr. 1988;47(3):502-508. 8. Vaidya A, Mulatero P, BaudrandR, Adler GK. The Expanding Spectrumof Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment. Endocr Rev. 2018;39(6):1057-1088. 9. Nishimoto K, Tomlins SA, Kuick R, et al. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc Natl Acad Sci U S A. 2015;112(33):E4591-4599. 10. Nanba K, Omata K, Else T, et al. Targeted Molecular Characterization of Aldosterone-Producing Adenomas in White Americans. J Clin Endocrinol Metab. 2018;103(10):3869-3876. 11. Takeda Y, Demura M, Wang F, et al. Epigenetic Regulation of Aldosterone Synthase Gene by Sodium and Angiotensin II. J AmHeart Assoc. 2018;7(10). 12. Carvajal C, Baudrand R, Fardella CE. Hiperaldosteronismo primario y otras formas de hipertension arterial endocrina. Vol 41. ARS MEDICA Revista De Ciencias Médicas2016. 13. Vaidya A, Carey RM. Evolution of thePrimary AldosteronismSyndrome: Updating the Approach. J Clin Endocrinol Metab. 2020;105(12). 14. Macchiavello S, Fardella C, Baudrand R. [Update in the clinical management of low renin hypertension]. Rev Med Chil. 2019;147(4):490-498. 15. Funder J. Primary aldosteronism. Trends Cardiovasc Med. 2021. 16. Dekkers T, Prejbisz A, Kool LJS, et al. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes Endocrinol. 2016;4(9):739-746. 17. Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689-699. 18. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6(1):51-59. 19. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-2068.
RkJQdWJsaXNoZXIy MTYwMjk1